Pang Yuxin, Han Zhibin, Xu Chen, Meng Jincheng, Qi Jiping
Department of Pathology, The First Affiliated Hospital of Harbin Medical University Harbin 150001, Heilongjiang, China.
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University Harbin 150001, Heilongjiang, China.
Am J Transl Res. 2024 Jun 15;16(6):2719-2726. doi: 10.62347/CAHC9133. eCollection 2024.
To study the therapeutic effectiveness of donepezil hydrochloride (DPZ) in combination with butylphthalide (BP) for the treatment of post-stroke cognitive impairment (PSCI).
In this retrospective study, the clinical data of 125 PSCI patients treated at the First Affiliated Hospital of Harbin Medical University from December 2019 to December 2023 were collected and analyzed. The patients were grouped into a joint group (n=75, receiving DPZ + BP) and a control group (n=50, receiving DPZ alone) according to their treatment regimen. Inter-group comparisons were then carried out from the perspectives of therapeutic effectiveness, safety (constipation, abdominal distension and pain, and gastrointestinal reactions), cognitive function (Montreal Cognitive Assessment Scale [MoCA], Chinese Stroke Scale [CSS]), Activities of Daily Living Scale (ADL), and serum biochemical indexes (neuron-specific enolase [NSE], high-sensitivity C-reactive protein [hs-CRP], nitric oxide [NO], and malondialdehyde [MDA]). In addition, a univariate analysis was carried out to identify factors affecting therapeutic effectiveness in PSCI patients.
The joint group showed significantly better therapeutic effectiveness compared to the control group (P<0.05). There was a significant correlation between the type of stroke, treatment method, and therapeutic effectiveness in PSCI patients (P<0.05). There was no significant difference in the total incidence of adverse reactions (P>0.05). After the treatment, compared to the control group, the joint group demonstrated significant improvements in MoCA and ADL scores (all P<0.05) and reductions in CSS scores and levels of NSE, hs-CRP, NO, and MDA (all P<0.05).
DPZ in combination with BP is highly effective for the treatment of PSCI. It positively affects cognitive function and ADL, alleviates neurological deficits, and reduces abnormal serum biochemical indices without increasing the risk of adverse reaction.
研究盐酸多奈哌齐（DPZ）联合丁苯酞（BP）治疗脑卒中后认知障碍（PSCI）的疗效。
本回顾性研究收集并分析了2019年12月至2023年12月在哈尔滨医科大学附属第一医院接受治疗的125例PSCI患者的临床资料。根据治疗方案将患者分为联合组（n = 75，接受DPZ + BP）和对照组（n = 50，仅接受DPZ）。然后从疗效、安全性（便秘、腹胀和疼痛以及胃肠道反应）、认知功能（蒙特利尔认知评估量表[MoCA]、中国卒中量表[CSS]）、日常生活活动量表（ADL）以及血清生化指标（神经元特异性烯醇化酶[NSE]、高敏C反应蛋白[hs-CRP]、一氧化氮[NO]和丙二醛[MDA]）等方面进行组间比较。此外，进行单因素分析以确定影响PSCI患者治疗效果的因素。
联合组的治疗效果明显优于对照组（P < 0.05）。PSCI患者的卒中类型、治疗方法与治疗效果之间存在显著相关性（P < 0.05）。不良反应总发生率无显著差异（P > 0.05）。治疗后，与对照组相比，联合组的MoCA和ADL评分显著改善（均P < 0.05），CSS评分以及NSE、hs-CRP、NO和MDA水平降低（均P < 0.05）。
DPZ联合BP治疗PSCI疗效显著。它对认知功能和ADL有积极影响，减轻神经功能缺损，降低血清生化指标异常，且不增加不良反应风险。
